One-year continuous inhaled nitric oxide for primary pulmonary hypertension

Area of Science:

• Cardiovascular Medicine
• Pulmonary Medicine
• Respiratory Therapy

Background:

• Primary pulmonary hypertension is a severe condition characterized by elevated pulmonary artery pressure.
• Exertional dyspnea and anasarca are common debilitating symptoms of pulmonary hypertension.
• Current treatments often involve continuous intravenous therapies with significant costs and potential side effects.

Observation:

• A 32-year-old male patient with primary pulmonary hypertension presented with severe exertional dyspnea and anasarca.
• An acute trial of inhaled nitric oxide (NO) demonstrated a modest reduction in mean pulmonary artery pressure.
• The patient was subsequently initiated on long-term inhaled NO therapy.

Findings:

• Within 20 days, inhaled NO therapy led to significant improvement in dyspnea, resolution of anasarca, and increased oxygenation (PaO2).
• After 12 months of continuous inhaled NO, the patient remained clinically stable.
• No adverse effects such as toxicity or tachyphylaxis were observed during the treatment period.

Implications:

• This case report suggests that prolonged inhaled nitric oxide therapy can be a safe and effective long-term treatment for primary pulmonary hypertension in adults.
• Continuous inhaled NO may represent a cost-effective alternative to continuous intravenous epoprostenol infusion.
• Further research is warranted to confirm these findings in larger patient cohorts and establish optimal treatment protocols.